Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced MelanomaGlobeNewsWire · 1 day ago
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026GlobeNewsWire · 5 days ago
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual MeetingGuruFocus · Oct 2, 2026
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin GainsMarketBeat · Sep 19, 2026
5 Biotech Stocks Worth Adding to Your Portfolio NowZacks Investment Research · Aug 26, 2026
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire · Aug 13, 2026Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.35 | -$0.63 | Miss |
| May 15, 2026 | -$0.62 | -$0.62 | Beat |
| Mar 27, 2026 | -$2.31 | -$1.21 | Beat |
| Nov 13, 2025 | -$2.00 | -$2.01 | Miss |
| Aug 13, 2025 | -$1.72 | -$3.24 | Miss |
| May 13, 2025 | -$2.02 | -$4.32 | Miss |